董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Hugh Griffith | 男 | Chief Executive Officer and Director | 55 | 102.25万 | 未持股 | 2023-04-04 |
| Cyrille Leperlier | 男 | Non-Executive Director | 69 | 6.04万 | 未持股 | 2023-04-04 |
| Bali Muralidhar | 男 | Non-Executive Director | 43 | 2.92万 | 未持股 | 2023-04-04 |
| Andrew Kay | 男 | Non-Executive Director and Chairman | 67 | 7.21万 | 未持股 | 2023-04-04 |
| Elliott Levy | -- | Non-Executive Director | 64 | 4.83万 | 未持股 | 2023-04-04 |
| Martin Mellish | 男 | Non-Executive Director | 66 | 4.45万 | 未持股 | 2023-04-04 |
| Adam George | 男 | Non-Executive Director | 53 | 5.27万 | 未持股 | 2023-04-04 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Hugh Griffith | 男 | Chief Executive Officer and Director | 55 | 102.25万 | 未持股 | 2023-04-04 |
| Donald Munoz | 男 | Chief Financial Officer | 54 | 未披露 | 未持股 | 2023-04-04 |
| Jeffrey Bloss | 男 | Chief Medical Officer | 66 | 未披露 | 未持股 | 2023-04-04 |
| David Harrison | 男 | Head of Translational Studies | 63 | 未披露 | 未持股 | 2023-04-04 |
董事简历
中英对照 | 中文 | 英文- Hugh Griffith
-
Hugh Griffith是我们的联合创始人，自2008年3月开始运营以来一直担任我们的首席执行官和董事会成员。此外，他目前担任Three Holdings Limited公司及其全资子公司Edixomed Limited公司和MedAnnex Limited公司（他于2009年共同创立的生物技术公司）的非执行董事。他也担任Alida Capital International公司（他于2009年成立的生物技术商业天使辛迪加）的董事。在创立Nucana之前，Griffith先生从2004年7月到2007年12月担任BioEnvision，Inc.（一家生物制药公司）的首席运营官，2007年12月该公司被健赞公司（现为赛诺菲）收购。他此前曾担任BioEnvision公司的商业董事（从2002年9月到2004年6月）。在此之前，Griffith先生曾于2002年1月至2002年7月雅培公司（现为艾伯维公司）（1995年10月至2001年12月）和Warner-Lambert Company（现为辉瑞公司）（1992年4月至1995年10月）担任多个高级商业职位。他目前任职于the Scottish LifeSciences Association的咨询委员会。Griffith先生在卡迪夫商学院（Cardiff Business School）获得工商管理硕士学位和工商管理硕士学位。the University of Stirling生物学荣誉。
Hugh Griffith is our co-founder and has served as our Chief Executive Officer and as a member of our board of directors since our operations began in March 2008. In addition, he currently serves as a non-executive director of Thirty Holdings Limited, EdixoMed Limited and MedAnnex Limited. Prior to founding NuCana, Mr. Griffith was Chief Operating Officer of Bioenvision, Inc., a biopharmaceutical company, from July 2004 until December 2007 when it was acquired by Genzyme Corporation now Sanofi. He previously served as Commercial Director of Bioenvision, Inc. from September 2002 to June 2004. Before that, Mr. Griffith held several senior commercial positions at Quantanova Limited, a biopharmaceutical company, from January 2002 to July 2002 Abbot Laboratories (now AbbVie Inc.) from October 1995 to December 2001 and Warner-Lambert Company (now Pfizer Inc.) from April 1992 to October 1995. He currently serves on the advisory board of the Scottish Lifesciences Association. In 2018 Mr. Griffith received a lifetime achievement award for ‘Outstanding Contribution to Life Sciences' by the Scottish Government. Mr. Griffith is a named inventor on over 398 patents and over 300 pending patent applications. He received an M.B.A. from Cardiff Business School and a B.Sc. Honours in Biology from the University of Stirling. - Hugh Griffith是我们的联合创始人，自2008年3月开始运营以来一直担任我们的首席执行官和董事会成员。此外，他目前担任Three Holdings Limited公司及其全资子公司Edixomed Limited公司和MedAnnex Limited公司（他于2009年共同创立的生物技术公司）的非执行董事。他也担任Alida Capital International公司（他于2009年成立的生物技术商业天使辛迪加）的董事。在创立Nucana之前，Griffith先生从2004年7月到2007年12月担任BioEnvision，Inc.（一家生物制药公司）的首席运营官，2007年12月该公司被健赞公司（现为赛诺菲）收购。他此前曾担任BioEnvision公司的商业董事（从2002年9月到2004年6月）。在此之前，Griffith先生曾于2002年1月至2002年7月雅培公司（现为艾伯维公司）（1995年10月至2001年12月）和Warner-Lambert Company（现为辉瑞公司）（1992年4月至1995年10月）担任多个高级商业职位。他目前任职于the Scottish LifeSciences Association的咨询委员会。Griffith先生在卡迪夫商学院（Cardiff Business School）获得工商管理硕士学位和工商管理硕士学位。the University of Stirling生物学荣誉。
- Hugh Griffith is our co-founder and has served as our Chief Executive Officer and as a member of our board of directors since our operations began in March 2008. In addition, he currently serves as a non-executive director of Thirty Holdings Limited, EdixoMed Limited and MedAnnex Limited. Prior to founding NuCana, Mr. Griffith was Chief Operating Officer of Bioenvision, Inc., a biopharmaceutical company, from July 2004 until December 2007 when it was acquired by Genzyme Corporation now Sanofi. He previously served as Commercial Director of Bioenvision, Inc. from September 2002 to June 2004. Before that, Mr. Griffith held several senior commercial positions at Quantanova Limited, a biopharmaceutical company, from January 2002 to July 2002 Abbot Laboratories (now AbbVie Inc.) from October 1995 to December 2001 and Warner-Lambert Company (now Pfizer Inc.) from April 1992 to October 1995. He currently serves on the advisory board of the Scottish Lifesciences Association. In 2018 Mr. Griffith received a lifetime achievement award for ‘Outstanding Contribution to Life Sciences' by the Scottish Government. Mr. Griffith is a named inventor on over 398 patents and over 300 pending patent applications. He received an M.B.A. from Cardiff Business School and a B.Sc. Honours in Biology from the University of Stirling.
- Cyrille Leperlier
-
Cyrille Leperlier自2018年5月以来一直担任我们的董事会成员。最近，他曾担任Sanofi公司的企业业务发展和并购集团的高级科学顾问，在那里，除其他交易外，他曾深入参与Sanofi公司收购Genzyme公司。在此之前，Leperlier博士担任Sanofi在日本的医疗总监，在加入Sanofi之前，Leperlier博士是Rhone Poulenc Rorer的医疗总监兼临床开发全球主管，之前曾在Takeda担任各种运营和医疗事务角色。Leperlier博士在巴黎大学圣安东尼医学院（University of Paris，Saint-Antoine School of Medicine）获得医学博士学位，并在巴黎医科大学（Medical University of Paris）获得生理学人类生物学硕士学位。他是公认的肿瘤药物开发、战略投资组合优先排序和业务发展专家，在多家全球生物技术和制药公司拥有丰富的领导经验。
Cyrille Leperlier has served as a member of our board of directors since May 2018. Dr. Leperlier also served as an operational investor with Jeito Capital and has served as the Chief Executive Officer of Divlal SAS since June 2020. From 2009 to 2016 Dr. Leperlier also served as Vice President of Medical Assessment for Corporate Strategy for Sanofi's Corporate Business Development and M&A Group, where, among other transactions, he was deeply involved in Sanofi's acquisition of Genzyme. Prior to this role, Dr. Leperlier served at Sanofi as Medical Director in Japan from 2007 to 2009 and Head of Medical Affairs, International Region from 2004 to 2007. Before joining Sanofi, Dr. Leperlier was Medical Director and Global Head of Clinical Development at Rhone Poulenc Rorer and previously worked for Takeda in a variety of operational and medical affairs roles. Dr. Leperlier received an M.D. from the University of Paris, Saint-Antoine School of Medicine and a Master in Human Biology major in physiology from the Medical University of Paris. - Cyrille Leperlier自2018年5月以来一直担任我们的董事会成员。最近，他曾担任Sanofi公司的企业业务发展和并购集团的高级科学顾问，在那里，除其他交易外，他曾深入参与Sanofi公司收购Genzyme公司。在此之前，Leperlier博士担任Sanofi在日本的医疗总监，在加入Sanofi之前，Leperlier博士是Rhone Poulenc Rorer的医疗总监兼临床开发全球主管，之前曾在Takeda担任各种运营和医疗事务角色。Leperlier博士在巴黎大学圣安东尼医学院（University of Paris，Saint-Antoine School of Medicine）获得医学博士学位，并在巴黎医科大学（Medical University of Paris）获得生理学人类生物学硕士学位。他是公认的肿瘤药物开发、战略投资组合优先排序和业务发展专家，在多家全球生物技术和制药公司拥有丰富的领导经验。
- Cyrille Leperlier has served as a member of our board of directors since May 2018. Dr. Leperlier also served as an operational investor with Jeito Capital and has served as the Chief Executive Officer of Divlal SAS since June 2020. From 2009 to 2016 Dr. Leperlier also served as Vice President of Medical Assessment for Corporate Strategy for Sanofi's Corporate Business Development and M&A Group, where, among other transactions, he was deeply involved in Sanofi's acquisition of Genzyme. Prior to this role, Dr. Leperlier served at Sanofi as Medical Director in Japan from 2007 to 2009 and Head of Medical Affairs, International Region from 2004 to 2007. Before joining Sanofi, Dr. Leperlier was Medical Director and Global Head of Clinical Development at Rhone Poulenc Rorer and previously worked for Takeda in a variety of operational and medical affairs roles. Dr. Leperlier received an M.D. from the University of Paris, Saint-Antoine School of Medicine and a Master in Human Biology major in physiology from the Medical University of Paris.
- Bali Muralidhar
-
Bali Muralidhar自2020年12月起担任我们的董事会成员。Muralidhar博士自2020年12月起担任Abingworth LLP Abingworth（一家致力于生命科学的国际投资集团）的管理合伙人。Muralidhar博士此前曾于2019年3月至2020年12月担任Abingworth的合伙人。在加入Abingworth之前，Muralidhar博士于2012年11月至2019年3月担任生命科学投资基金MVM Partners LLP（MVM）的高级合伙人。在加入MVM之前，Muralidhar博士从2011年4月到2012年11月是Bain Capital LP&8217；S（一家私人多资产另类投资公司，杠杆收购团队，专注于梦百合）的成员。Muralidhar博士自2020年10月起担任Nucana Plc董事，自2020年2月起担任SpruceBiosciences，Inc.董事，自2019年8月起担任Exicure，Inc.董事，两人均为上市生物技术公司。Muralidhar博士此前于2014年3月至2018年4月担任瑞典公共生物制药公司Wilson Therapeutics的董事会成员，并于2017年5月至2019年12月担任在维也纳证券交易所上市的法国生物技术公司Valneva SE的董事会成员。Muralidhar博士在牛津大学（University of Oxford）获得临床医学学位，并在剑桥大学（University of Cambridge）MRC癌细胞单元获得转化癌症研究博士学位。
Bali Muralidhar has served as a member of our board of directors since October 2020. Dr. Muralidhar is a Managing Partner at Abingworth LLP, or Abingworth, a transatlantic investment group dedicated to life sciences. Prior to joining Abingworth, Dr. Muralidhar was a senior partner at MVM Partners LLP, or MVM, from November 2012 to March 2019. He represents Abingworth on the boards of Exicure Inc. Nasdaq: XCUR, Spruce Biosciences (Nasdaq: SPRB), Reneo Pharmaceuticals and Anjarium Biosciences. Prior to MVM, he was a member of Bain Capital LP's leveraged buyout team, focusing on healthcare from April 2011 to November 2012. Dr. Muralidhar previously served on the supervisory board of Valneva SE, a French biotechnology company traded on Euronext and Wilson Therapeutics traded in Nasdaq OMX. Dr. Muralidhar earned a degree in clinical medicine from the University of Oxford and has a Ph.D. in translational cancer research from the MRC Cancer Cell Unit, University of Cambridge. - Bali Muralidhar自2020年12月起担任我们的董事会成员。Muralidhar博士自2020年12月起担任Abingworth LLP Abingworth（一家致力于生命科学的国际投资集团）的管理合伙人。Muralidhar博士此前曾于2019年3月至2020年12月担任Abingworth的合伙人。在加入Abingworth之前，Muralidhar博士于2012年11月至2019年3月担任生命科学投资基金MVM Partners LLP（MVM）的高级合伙人。在加入MVM之前，Muralidhar博士从2011年4月到2012年11月是Bain Capital LP&8217；S（一家私人多资产另类投资公司，杠杆收购团队，专注于梦百合）的成员。Muralidhar博士自2020年10月起担任Nucana Plc董事，自2020年2月起担任SpruceBiosciences，Inc.董事，自2019年8月起担任Exicure，Inc.董事，两人均为上市生物技术公司。Muralidhar博士此前于2014年3月至2018年4月担任瑞典公共生物制药公司Wilson Therapeutics的董事会成员，并于2017年5月至2019年12月担任在维也纳证券交易所上市的法国生物技术公司Valneva SE的董事会成员。Muralidhar博士在牛津大学（University of Oxford）获得临床医学学位，并在剑桥大学（University of Cambridge）MRC癌细胞单元获得转化癌症研究博士学位。
- Bali Muralidhar has served as a member of our board of directors since October 2020. Dr. Muralidhar is a Managing Partner at Abingworth LLP, or Abingworth, a transatlantic investment group dedicated to life sciences. Prior to joining Abingworth, Dr. Muralidhar was a senior partner at MVM Partners LLP, or MVM, from November 2012 to March 2019. He represents Abingworth on the boards of Exicure Inc. Nasdaq: XCUR, Spruce Biosciences (Nasdaq: SPRB), Reneo Pharmaceuticals and Anjarium Biosciences. Prior to MVM, he was a member of Bain Capital LP's leveraged buyout team, focusing on healthcare from April 2011 to November 2012. Dr. Muralidhar previously served on the supervisory board of Valneva SE, a French biotechnology company traded on Euronext and Wilson Therapeutics traded in Nasdaq OMX. Dr. Muralidhar earned a degree in clinical medicine from the University of Oxford and has a Ph.D. in translational cancer research from the MRC Cancer Cell Unit, University of Cambridge.
- Andrew Kay
-
Andrew Kay自2020年12月起担任我们的董事会主席。Kay先生自2017年9月起担任Nerre Therapeutics董事会主席，自2015年8月起担任Blueberry Therapeutics董事会主席。从2019年1月到2020年9月，他担任Kandy Therapeutics的相同职位，该公司是一家被Bayer收购的生物技术公司。2015年9月至2018年6月，Kay先生担任Wilson Therapeutics（生物制药公司，于2018年被Alexion Pharmaceuticals收购）的董事会主席。在此之前，Kay先生从2009年1月到2014年5月担任Algeta的总裁兼首席执行官。加入Algeta之前，Kay先生曾担任Novartis的市场营销与销售全球主管、医疗保健委员会和制药执行委员会的成员（从1999年到2003年），并在欧洲和美国担任过其他几个高级商业职位，曾任职Renovo，阿斯利康，Eli Lilly，山德士和靴子。凯先生在诺丁汉大学获得了药学荣誉学士学位。我们认为，Kay先生具有特定的特质，有资格担任我们董事会的成员，包括他在生物技术和制药公司的丰富经验。
Andrew Kay has served as Chairman of our board of directors since December 2020. Mr. Kay has served as Chairman of the Board of NeRRe Therapeutics since September 2017 and as Chairman of the Board of Blueberry Therapeutics since August 2015. From January 2019 to September 2020 he held the same role for KaNDy Therapeutics, a biotechnology company that was acquired by Bayer. From September 2015 to June 2018 Mr. Kay served as Chairman of the Board of Wilson Therapeutics, a biopharmaceutical company acquired by Alexion Pharmaceuticals in 2018. Prior to that, Mr. Kay served as the President and Chief Executive Officer for Algeta from January 2009 to May 2014. Prior to Algeta, Mr. Kay was the Global Head of Marketing and Sales and a Member of the Healthcare Committee and Pharmaceutical Executive Committee at Novartis 1999 to 2003 and held several other senior commercial positions in Europe and the U.S. having worked at Renovo, AstraZeneca, Eli Lilly, Sandoz and Boots. Mr. Kay earned his Bachelor of Honors in Pharmacy from Nottingham University. - Andrew Kay自2020年12月起担任我们的董事会主席。Kay先生自2017年9月起担任Nerre Therapeutics董事会主席，自2015年8月起担任Blueberry Therapeutics董事会主席。从2019年1月到2020年9月，他担任Kandy Therapeutics的相同职位，该公司是一家被Bayer收购的生物技术公司。2015年9月至2018年6月，Kay先生担任Wilson Therapeutics（生物制药公司，于2018年被Alexion Pharmaceuticals收购）的董事会主席。在此之前，Kay先生从2009年1月到2014年5月担任Algeta的总裁兼首席执行官。加入Algeta之前，Kay先生曾担任Novartis的市场营销与销售全球主管、医疗保健委员会和制药执行委员会的成员（从1999年到2003年），并在欧洲和美国担任过其他几个高级商业职位，曾任职Renovo，阿斯利康，Eli Lilly，山德士和靴子。凯先生在诺丁汉大学获得了药学荣誉学士学位。我们认为，Kay先生具有特定的特质，有资格担任我们董事会的成员，包括他在生物技术和制药公司的丰富经验。
- Andrew Kay has served as Chairman of our board of directors since December 2020. Mr. Kay has served as Chairman of the Board of NeRRe Therapeutics since September 2017 and as Chairman of the Board of Blueberry Therapeutics since August 2015. From January 2019 to September 2020 he held the same role for KaNDy Therapeutics, a biotechnology company that was acquired by Bayer. From September 2015 to June 2018 Mr. Kay served as Chairman of the Board of Wilson Therapeutics, a biopharmaceutical company acquired by Alexion Pharmaceuticals in 2018. Prior to that, Mr. Kay served as the President and Chief Executive Officer for Algeta from January 2009 to May 2014. Prior to Algeta, Mr. Kay was the Global Head of Marketing and Sales and a Member of the Healthcare Committee and Pharmaceutical Executive Committee at Novartis 1999 to 2003 and held several other senior commercial positions in Europe and the U.S. having worked at Renovo, AstraZeneca, Eli Lilly, Sandoz and Boots. Mr. Kay earned his Bachelor of Honors in Pharmacy from Nottingham University.
- Elliott Levy
-
Elliott Levy自2021年11月以来一直担任我们的董事会成员。Levy博士于2020年6月至2021年5月担任生物技术公司副总裁0的研发、战略和运营高级副总裁。在2020年6月之前，Levy博士还是副总裁0的全球发展高级副总裁。Levy博士目前是Omega Therapeutics，Inc.的董事会成员。纳斯达克股票代码：OMGA，并担任Intrepid Alliance，Inc.的首席执行官，该公司是一家非营利组织，其目标是促进未来大流行药物的小分子疗法的开发。Levy博士担任联生物（纳斯达克股票代码：LIAN）的战略顾问和科学顾问委员会成员，并且是早期风险投资公司5AM Ventures的风险合伙人。Levy博士在生物制药行业研究药物的临床开发和监管批准方面拥有24年的经验。Levy博士拥有耶鲁大学医学院的医学博士学位和文学学士学位。耶鲁大学历史学博士。
Elliott Levy has served as a member of our board of directors since November 2021. Dr. Levy has been a Senior Vice President of Research & Development, Strategy and Operations of Amgen Inc., a biotechnology firm from June 2020 to May 2021. Prior to June 2020 Dr. Levy was also a Senior Vice President of Global Development at Amgen Inc. Dr. Levy is currently on the board of directors at Omega Therapeutics, Inc. Nasdaq: OMGA, and serves as CEO of Intrepid Alliance, Inc., a non-profit whose objective is to facilitate the development of small molecule therapeutics for future pandemic agents. Dr. Levy serves as a strategic advisor and member of the Scientific Advisory Board of LianBio (Nasdaq: LIAN), and is a venture partner of 5AM Ventures, an early stage venture firm. Dr. Levy has 24 years' experience in the clinical development and regulatory approval of investigational medicines in the biopharmaceutical industry. Dr. Levy holds an M.D. from the Yale School of Medicine and a B.A. in History from Yale College. - Elliott Levy自2021年11月以来一直担任我们的董事会成员。Levy博士于2020年6月至2021年5月担任生物技术公司副总裁0的研发、战略和运营高级副总裁。在2020年6月之前，Levy博士还是副总裁0的全球发展高级副总裁。Levy博士目前是Omega Therapeutics，Inc.的董事会成员。纳斯达克股票代码：OMGA，并担任Intrepid Alliance，Inc.的首席执行官，该公司是一家非营利组织，其目标是促进未来大流行药物的小分子疗法的开发。Levy博士担任联生物（纳斯达克股票代码：LIAN）的战略顾问和科学顾问委员会成员，并且是早期风险投资公司5AM Ventures的风险合伙人。Levy博士在生物制药行业研究药物的临床开发和监管批准方面拥有24年的经验。Levy博士拥有耶鲁大学医学院的医学博士学位和文学学士学位。耶鲁大学历史学博士。
- Elliott Levy has served as a member of our board of directors since November 2021. Dr. Levy has been a Senior Vice President of Research & Development, Strategy and Operations of Amgen Inc., a biotechnology firm from June 2020 to May 2021. Prior to June 2020 Dr. Levy was also a Senior Vice President of Global Development at Amgen Inc. Dr. Levy is currently on the board of directors at Omega Therapeutics, Inc. Nasdaq: OMGA, and serves as CEO of Intrepid Alliance, Inc., a non-profit whose objective is to facilitate the development of small molecule therapeutics for future pandemic agents. Dr. Levy serves as a strategic advisor and member of the Scientific Advisory Board of LianBio (Nasdaq: LIAN), and is a venture partner of 5AM Ventures, an early stage venture firm. Dr. Levy has 24 years' experience in the clinical development and regulatory approval of investigational medicines in the biopharmaceutical industry. Dr. Levy holds an M.D. from the Yale School of Medicine and a B.A. in History from Yale College.
- Martin Mellish
-
Martin Mellish，自1994年起担任私人投资办公室Aspen Advisory Services Ltd.的创始董事和现任董事长。Mellish先生担任NuCana Ltd（纳斯达克：NCNA；审计委员会成员）、Spectral AI Inc.（纳斯达克：MDAI，审计委员会主席）；Levitronix Technologies Inc.（审计委员会主席）、Alturki Holding（审计委员会主席）、Saudi Readymix Concrete Company（审计委员会主席）和Kensington Green（Management）Limited（Estates Environment & Security Committee主席）的非执行董事。无偿他是麻萨诸塞州总医院国际顾问委员会的成员。1984年至1992年，Mellish先生在Alturki Holding（一家位于沙特阿拉伯的工业投资公司）担任财务总监兼首席财务官。Mellish先生在普华永道接受培训，并于1983年注册为注册会计师（马萨诸塞州）。他拥有达特茅斯学院医学院和商学院的医疗保健提供科学硕士学位、麻省理工学院的SM（管理学）学位和理学硕士学位。东北大学（会计学）。
Martin Mellish has served as founding director and now chairman of Aspen Advisory Services Ltd., a private investment office, since 1994. Mr. Mellish serves as a non executive director of NuCana Ltd (Nasdaq: NCNA; member, Audit Committee), Spectral AI Inc. (Nasdaq: MDAI, chair, Audit Committee), Levitronix Technologies Inc. (chair, Audit Committee), Alturki Holding (chair, Audit Committee), Saudi Readymix Concrete Company (chair, Audit Committee), and Kensington Green (Management) Limited (chair, Estates Environment & Security Committee). Pro bono, he serves as a member of the International Advisory Council of the Massachetts General Hospital. From 1984 to 1992 Mr. Mellish was Financial Controller and Chief Financial Officer of Alturki Holding, an indtrial investment company based in Saudi Arabia. Mr. Mellish trained at Price Waterhoe and was registered as a Certified Public Accountant (Mass.) in 1983. He holds as M.Sc. in Health Care Delivery Science from the schools of medicine and biness at Dartmouth College, an SM (Management) from the Massachetts Institute of Technology, and an M.Sc. (Accounting) from Northeastern University. - Martin Mellish，自1994年起担任私人投资办公室Aspen Advisory Services Ltd.的创始董事和现任董事长。Mellish先生担任NuCana Ltd（纳斯达克：NCNA；审计委员会成员）、Spectral AI Inc.（纳斯达克：MDAI，审计委员会主席）；Levitronix Technologies Inc.（审计委员会主席）、Alturki Holding（审计委员会主席）、Saudi Readymix Concrete Company（审计委员会主席）和Kensington Green（Management）Limited（Estates Environment & Security Committee主席）的非执行董事。无偿他是麻萨诸塞州总医院国际顾问委员会的成员。1984年至1992年，Mellish先生在Alturki Holding（一家位于沙特阿拉伯的工业投资公司）担任财务总监兼首席财务官。Mellish先生在普华永道接受培训，并于1983年注册为注册会计师（马萨诸塞州）。他拥有达特茅斯学院医学院和商学院的医疗保健提供科学硕士学位、麻省理工学院的SM（管理学）学位和理学硕士学位。东北大学（会计学）。
- Martin Mellish has served as founding director and now chairman of Aspen Advisory Services Ltd., a private investment office, since 1994. Mr. Mellish serves as a non executive director of NuCana Ltd (Nasdaq: NCNA; member, Audit Committee), Spectral AI Inc. (Nasdaq: MDAI, chair, Audit Committee), Levitronix Technologies Inc. (chair, Audit Committee), Alturki Holding (chair, Audit Committee), Saudi Readymix Concrete Company (chair, Audit Committee), and Kensington Green (Management) Limited (chair, Estates Environment & Security Committee). Pro bono, he serves as a member of the International Advisory Council of the Massachetts General Hospital. From 1984 to 1992 Mr. Mellish was Financial Controller and Chief Financial Officer of Alturki Holding, an indtrial investment company based in Saudi Arabia. Mr. Mellish trained at Price Waterhoe and was registered as a Certified Public Accountant (Mass.) in 1983. He holds as M.Sc. in Health Care Delivery Science from the schools of medicine and biness at Dartmouth College, an SM (Management) from the Massachetts Institute of Technology, and an M.Sc. (Accounting) from Northeastern University.
- Adam George
-
Adam George自2018年4月起担任Nucana Plc董事会成员。George先生于2017年3月至2020年12月担任GW Pharmaceutical英国董事总经理，2007年9月至2020年12月担任秘书，2012年至2017年3月担任首席财务官,2007年至2012年担任财务总监。GW Pharmaceuticals是一家生物制药公司，专注于从其专有的大麻素产品平台在广泛的疾病领域发现、开发和商业化新疗法。此外，George先生自2021年12月起担任Psi Pharmaceuticals Ltd董事会主席和首席执行官，自2021年6月起担任Beckley Psytech Ltd董事会成员。在加入GW Pharmaceuticals之前，George在上市公司和私营公司担任过多个高级财务职务。George先生拥有Bristol 大学生物学学士学位，是一名特许会计师。他还担任NuCana审计委员会主席。
Adam George has served as a member of Nucana Plc board of directors since April 2018. Mr. George served as GW Pharmaceutical's UK Managing Director from March 2017 to December 2020 Company Secretary from September 2007 to December 2020 Chief Financial Officer from 2012 to March 2017 and Financial Controller from 2007 to 2012. GW Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. In addition, Mr. George has served as chairman of the board of directors and chief executive officer of Psi Pharmaceuticals Ltd since December 2021 and as a member of the board of directors of Beckley Psytech Ltd since June 2021. Before joining GW Pharmaceuticals, Mr. George held several senior finance roles within both public and private companies. Mr. George holds a BSc. in Biology from Bristol University and is a Chartered Accountant. He also serves as Chairman of NuCana's Audit Committee. - Adam George自2018年4月起担任Nucana Plc董事会成员。George先生于2017年3月至2020年12月担任GW Pharmaceutical英国董事总经理，2007年9月至2020年12月担任秘书，2012年至2017年3月担任首席财务官,2007年至2012年担任财务总监。GW Pharmaceuticals是一家生物制药公司，专注于从其专有的大麻素产品平台在广泛的疾病领域发现、开发和商业化新疗法。此外，George先生自2021年12月起担任Psi Pharmaceuticals Ltd董事会主席和首席执行官，自2021年6月起担任Beckley Psytech Ltd董事会成员。在加入GW Pharmaceuticals之前，George在上市公司和私营公司担任过多个高级财务职务。George先生拥有Bristol 大学生物学学士学位，是一名特许会计师。他还担任NuCana审计委员会主席。
- Adam George has served as a member of Nucana Plc board of directors since April 2018. Mr. George served as GW Pharmaceutical's UK Managing Director from March 2017 to December 2020 Company Secretary from September 2007 to December 2020 Chief Financial Officer from 2012 to March 2017 and Financial Controller from 2007 to 2012. GW Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. In addition, Mr. George has served as chairman of the board of directors and chief executive officer of Psi Pharmaceuticals Ltd since December 2021 and as a member of the board of directors of Beckley Psytech Ltd since June 2021. Before joining GW Pharmaceuticals, Mr. George held several senior finance roles within both public and private companies. Mr. George holds a BSc. in Biology from Bristol University and is a Chartered Accountant. He also serves as Chairman of NuCana's Audit Committee.
高管简历
中英对照 | 中文 | 英文- Hugh Griffith
Hugh Griffith是我们的联合创始人，自2008年3月开始运营以来一直担任我们的首席执行官和董事会成员。此外，他目前担任Three Holdings Limited公司及其全资子公司Edixomed Limited公司和MedAnnex Limited公司（他于2009年共同创立的生物技术公司）的非执行董事。他也担任Alida Capital International公司（他于2009年成立的生物技术商业天使辛迪加）的董事。在创立Nucana之前，Griffith先生从2004年7月到2007年12月担任BioEnvision，Inc.（一家生物制药公司）的首席运营官，2007年12月该公司被健赞公司（现为赛诺菲）收购。他此前曾担任BioEnvision公司的商业董事（从2002年9月到2004年6月）。在此之前，Griffith先生曾于2002年1月至2002年7月雅培公司（现为艾伯维公司）（1995年10月至2001年12月）和Warner-Lambert Company（现为辉瑞公司）（1992年4月至1995年10月）担任多个高级商业职位。他目前任职于the Scottish LifeSciences Association的咨询委员会。Griffith先生在卡迪夫商学院（Cardiff Business School）获得工商管理硕士学位和工商管理硕士学位。the University of Stirling生物学荣誉。
Hugh Griffith is our co-founder and has served as our Chief Executive Officer and as a member of our board of directors since our operations began in March 2008. In addition, he currently serves as a non-executive director of Thirty Holdings Limited, EdixoMed Limited and MedAnnex Limited. Prior to founding NuCana, Mr. Griffith was Chief Operating Officer of Bioenvision, Inc., a biopharmaceutical company, from July 2004 until December 2007 when it was acquired by Genzyme Corporation now Sanofi. He previously served as Commercial Director of Bioenvision, Inc. from September 2002 to June 2004. Before that, Mr. Griffith held several senior commercial positions at Quantanova Limited, a biopharmaceutical company, from January 2002 to July 2002 Abbot Laboratories (now AbbVie Inc.) from October 1995 to December 2001 and Warner-Lambert Company (now Pfizer Inc.) from April 1992 to October 1995. He currently serves on the advisory board of the Scottish Lifesciences Association. In 2018 Mr. Griffith received a lifetime achievement award for ‘Outstanding Contribution to Life Sciences' by the Scottish Government. Mr. Griffith is a named inventor on over 398 patents and over 300 pending patent applications. He received an M.B.A. from Cardiff Business School and a B.Sc. Honours in Biology from the University of Stirling.- Hugh Griffith是我们的联合创始人，自2008年3月开始运营以来一直担任我们的首席执行官和董事会成员。此外，他目前担任Three Holdings Limited公司及其全资子公司Edixomed Limited公司和MedAnnex Limited公司（他于2009年共同创立的生物技术公司）的非执行董事。他也担任Alida Capital International公司（他于2009年成立的生物技术商业天使辛迪加）的董事。在创立Nucana之前，Griffith先生从2004年7月到2007年12月担任BioEnvision，Inc.（一家生物制药公司）的首席运营官，2007年12月该公司被健赞公司（现为赛诺菲）收购。他此前曾担任BioEnvision公司的商业董事（从2002年9月到2004年6月）。在此之前，Griffith先生曾于2002年1月至2002年7月雅培公司（现为艾伯维公司）（1995年10月至2001年12月）和Warner-Lambert Company（现为辉瑞公司）（1992年4月至1995年10月）担任多个高级商业职位。他目前任职于the Scottish LifeSciences Association的咨询委员会。Griffith先生在卡迪夫商学院（Cardiff Business School）获得工商管理硕士学位和工商管理硕士学位。the University of Stirling生物学荣誉。
- Hugh Griffith is our co-founder and has served as our Chief Executive Officer and as a member of our board of directors since our operations began in March 2008. In addition, he currently serves as a non-executive director of Thirty Holdings Limited, EdixoMed Limited and MedAnnex Limited. Prior to founding NuCana, Mr. Griffith was Chief Operating Officer of Bioenvision, Inc., a biopharmaceutical company, from July 2004 until December 2007 when it was acquired by Genzyme Corporation now Sanofi. He previously served as Commercial Director of Bioenvision, Inc. from September 2002 to June 2004. Before that, Mr. Griffith held several senior commercial positions at Quantanova Limited, a biopharmaceutical company, from January 2002 to July 2002 Abbot Laboratories (now AbbVie Inc.) from October 1995 to December 2001 and Warner-Lambert Company (now Pfizer Inc.) from April 1992 to October 1995. He currently serves on the advisory board of the Scottish Lifesciences Association. In 2018 Mr. Griffith received a lifetime achievement award for ‘Outstanding Contribution to Life Sciences' by the Scottish Government. Mr. Griffith is a named inventor on over 398 patents and over 300 pending patent applications. He received an M.B.A. from Cardiff Business School and a B.Sc. Honours in Biology from the University of Stirling.
- Donald Munoz
Donald Munoz自2015年10月起担任我们的首席财务官。在加入Nucana之前，Munoz先生于2014年9月至2015年9月担任Noxxon Pharma AG（现为Noxxon Pharma N.V.，一家生物制药公司）的集团首席财务官。在此之前，他曾于2012年8月至2014年9月担任Summer Street Research Partners（一家专注于梦百合的投资银行和机构证券公司）投资银行业务主管。Munoz先生此前曾于2009年至2011年担任Cowen and Company，LLC和Leerink Partners LLC的董事总经理，领导医疗技术投资银行业务。在此之前，他在Alex.Brown&Sons及其继任者德意志银行证券（Deutsche Bank Securities）的梦百合投资银行集团工作了大约10年。Munoz先生在哥伦比亚商学院（Columbia Business School）获得金融与会计工商管理硕士学位，并在达特茅斯学院（Dartmouth College）获得工商管理学士学位。
Donald Munoz has served as our Chief Financial Officer since October 2015. Mr. Munoz has served as Director of Enterin, Inc. since April 2021. Prior to joining NuCana, Mr. Munoz served as Group Chief Financial Officer of NOXXON Pharma AG now NOXXON Pharma N.V., a biopharmaceutical company, from September 2014 to September 2015. Before that, he was Head of Investment Banking at Summer Street Research Partners, an investment banking and institutional securities firm focused exclusively on healthcare, from August 2012 to September 2014. Mr. Munoz previously served as a Managing Director leading the medical technology investment banking franchises at Cowen and Company, LLC from 2009 to 2011 and Leerink Partners LLC from 2005 to 2009. Prior to that, he spent approximately ten years in the healthcare investment banking group at Alex. Brown & Sons and its successor, Deutsche Bank Securities. Mr. Munoz received an M.B.A. in Finance and Accounting from Columbia Business School and a B.A. from Dartmouth College.- Donald Munoz自2015年10月起担任我们的首席财务官。在加入Nucana之前，Munoz先生于2014年9月至2015年9月担任Noxxon Pharma AG（现为Noxxon Pharma N.V.，一家生物制药公司）的集团首席财务官。在此之前，他曾于2012年8月至2014年9月担任Summer Street Research Partners（一家专注于梦百合的投资银行和机构证券公司）投资银行业务主管。Munoz先生此前曾于2009年至2011年担任Cowen and Company，LLC和Leerink Partners LLC的董事总经理，领导医疗技术投资银行业务。在此之前，他在Alex.Brown&Sons及其继任者德意志银行证券（Deutsche Bank Securities）的梦百合投资银行集团工作了大约10年。Munoz先生在哥伦比亚商学院（Columbia Business School）获得金融与会计工商管理硕士学位，并在达特茅斯学院（Dartmouth College）获得工商管理学士学位。
- Donald Munoz has served as our Chief Financial Officer since October 2015. Mr. Munoz has served as Director of Enterin, Inc. since April 2021. Prior to joining NuCana, Mr. Munoz served as Group Chief Financial Officer of NOXXON Pharma AG now NOXXON Pharma N.V., a biopharmaceutical company, from September 2014 to September 2015. Before that, he was Head of Investment Banking at Summer Street Research Partners, an investment banking and institutional securities firm focused exclusively on healthcare, from August 2012 to September 2014. Mr. Munoz previously served as a Managing Director leading the medical technology investment banking franchises at Cowen and Company, LLC from 2009 to 2011 and Leerink Partners LLC from 2005 to 2009. Prior to that, he spent approximately ten years in the healthcare investment banking group at Alex. Brown & Sons and its successor, Deutsche Bank Securities. Mr. Munoz received an M.B.A. in Finance and Accounting from Columbia Business School and a B.A. from Dartmouth College.
- Jeffrey Bloss
Jeffrey Bloss，自2021年8月起担任我们的首席医疗官。此外，他在多家生物制药公司拥有超过20年的肿瘤学领导经验。在加入NuCana之前，Bloss博士于2018年8月至2021年8月担任风险投资支持的临床阶段肿瘤公司Tarveda Therapuetics的首席医疗官。在加入Tarveda之前，Bloss博士于2017年6月至2018年8月担任Aegerion Pharmaceuticals的首席医疗官兼医疗事务高级副总裁。Bloss博士在美国空军威尔福德霍尔医学中心完成了妇产科住院医师培训，并在加州大学欧文分校完成了妇科肿瘤学奖学金。Bloss博士获得了托马斯杰斐逊大学医学院的医学博士学位和理学学士学位。来自朱尼亚塔学院。
Jeffrey Bloss, has served as our Chief Medical Officer since August, 2021. In addition, he has over 20 years of leadership experience in oncology at multiple biopharmaceutical companies. Immediately prior to joining NuCana, Dr. Bloss served as Chief Medical Officer of Tarveda Therapuetics a venture-backed clinical stage oncology company from August 2018 to August 2021. Prior to Tarveda, Dr. Bloss was Chief Medical Officer and Senior Vice President, Medical Affairs at Aegerion Pharmaceuticals from June 2017 to August 2018. Dr. Bloss completed his Residency in Obstetrics & Gynecology at Wilford Hall USAF Medical Center and his Fellowship in Gynecologic Oncology at the University of California, Irvine. Dr. Bloss received his M.D. from Thomas Jefferson University Medical College and B.S. from Juniata College.- Jeffrey Bloss，自2021年8月起担任我们的首席医疗官。此外，他在多家生物制药公司拥有超过20年的肿瘤学领导经验。在加入NuCana之前，Bloss博士于2018年8月至2021年8月担任风险投资支持的临床阶段肿瘤公司Tarveda Therapuetics的首席医疗官。在加入Tarveda之前，Bloss博士于2017年6月至2018年8月担任Aegerion Pharmaceuticals的首席医疗官兼医疗事务高级副总裁。Bloss博士在美国空军威尔福德霍尔医学中心完成了妇产科住院医师培训，并在加州大学欧文分校完成了妇科肿瘤学奖学金。Bloss博士获得了托马斯杰斐逊大学医学院的医学博士学位和理学学士学位。来自朱尼亚塔学院。
- Jeffrey Bloss, has served as our Chief Medical Officer since August, 2021. In addition, he has over 20 years of leadership experience in oncology at multiple biopharmaceutical companies. Immediately prior to joining NuCana, Dr. Bloss served as Chief Medical Officer of Tarveda Therapuetics a venture-backed clinical stage oncology company from August 2018 to August 2021. Prior to Tarveda, Dr. Bloss was Chief Medical Officer and Senior Vice President, Medical Affairs at Aegerion Pharmaceuticals from June 2017 to August 2018. Dr. Bloss completed his Residency in Obstetrics & Gynecology at Wilford Hall USAF Medical Center and his Fellowship in Gynecologic Oncology at the University of California, Irvine. Dr. Bloss received his M.D. from Thomas Jefferson University Medical College and B.S. from Juniata College.
- David Harrison
David Harrison，自2017年12月起担任我们的转化研究主管。从2019年2月起，Harrison博士一直担任Icaird大学的主任和研究团队负责人，研究与放射学和病理学相关的人工智能。自2015年5月以来，哈里森博士一直担任英国公共致癌性委员会与癌症相关的政府咨询委员会主席。Harrison博士自2014年4月起担任膳食补充剂供应商BeneOx Ltd的研发总监。此外，哈里森博士自2012年5月起担任圣安德鲁斯大学病理学教授。Harrison博士在伦敦皇家病理学家学院完成了病理学研究，并在爱丁堡大学获得了医学博士学位和医学与外科学士学位。
David Harrison, has served as our Head of Translational Studies since December 2017. From February 2019 Dr. Harrison has been a Director and research team leader at iCAIRD University where he researches artificial intelligence relevant to radiology and pathology. Dr. Harrison has served as Chair of the Government advisory committee relating to cancer for the Public England Committee Carcinogenicity, since May 2015. Dr. Harrison has been a Director of Research & Development at Beneox Ltd, a dietary supplement supplier, since April 2014. In addition, Dr. Harrison has served as a professor of Pathology at the University of St. Andrews, since May 2012. Dr. Harrison completed his fellowship in Pathology at the Royal College of Pathologists, London, and received his M.D. and a Bachelor of Medicine and Surgery from the University of Edinburgh.- David Harrison，自2017年12月起担任我们的转化研究主管。从2019年2月起，Harrison博士一直担任Icaird大学的主任和研究团队负责人，研究与放射学和病理学相关的人工智能。自2015年5月以来，哈里森博士一直担任英国公共致癌性委员会与癌症相关的政府咨询委员会主席。Harrison博士自2014年4月起担任膳食补充剂供应商BeneOx Ltd的研发总监。此外，哈里森博士自2012年5月起担任圣安德鲁斯大学病理学教授。Harrison博士在伦敦皇家病理学家学院完成了病理学研究，并在爱丁堡大学获得了医学博士学位和医学与外科学士学位。
- David Harrison, has served as our Head of Translational Studies since December 2017. From February 2019 Dr. Harrison has been a Director and research team leader at iCAIRD University where he researches artificial intelligence relevant to radiology and pathology. Dr. Harrison has served as Chair of the Government advisory committee relating to cancer for the Public England Committee Carcinogenicity, since May 2015. Dr. Harrison has been a Director of Research & Development at Beneox Ltd, a dietary supplement supplier, since April 2014. In addition, Dr. Harrison has served as a professor of Pathology at the University of St. Andrews, since May 2012. Dr. Harrison completed his fellowship in Pathology at the Royal College of Pathologists, London, and received his M.D. and a Bachelor of Medicine and Surgery from the University of Edinburgh.